Table 1.
Patient and clinical characteristics of pediatrics with hematological diseases.
| Characteristic | Total (n = 241) | IFD (n = 26) | Non-IFD (n = 215) | P value |
|---|---|---|---|---|
| Age (yr) | ||||
| Median (min, max) | 5.4 (0.3, 16.0) | 6.8 (1.3, 15.1) | 5.2 (0.3, 16.0) | .233 |
| Sex, n (%) | ||||
| Male | 127 (52.7) | 15 (57.7) | 112 (52.1) | .589 |
| Female | 114 (47.3) | 11 (42.3) | 103 (47.9) | |
| Underlying disease, n (%) | ||||
| ALL | 150 (62.2) | 12 (46.2) | 138 (64.2) | .231 |
| AML | 35 (14.5) | 4 (15.4) | 31 (14.4) | |
| Relapsed leukemia | 31 (12.9) | 6 (23.0) | 25 (11.6) | |
| SAA | 25 (10.4) | 4 (15.4) | 21 (9.8) | |
| Antifungal prophylaxis, n (%) | ||||
| Yes | 49 (20.3) | 4 (15.4) | 45 (20.9) | .685 |
| No | 192 (79.7) | 22 (84.6) | 170 (79.1) | |
| Drug, n (%) | ||||
| Itraconazole | 25 (51.0) | 2 (50.0) | 23 (51.1) | .211 |
| Fluconazole | 14 (28.6) | 0 (0) | 14 (31.1) | |
| Posaconazole | 10 (20.4) | 2 (50.0) | 8 (17.8) | |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; IFD, invasive fungal disease; SAA, severe aplastic anemia.